Literature DB >> 17204698

A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer.

Shuntaro Oka1, Ryota Hattori, Fumie Kurosaki, Masahito Toyama, Larry A Williams, Weiping Yu, John R Votaw, Yasunori Yoshida, Mark M Goodman, Osamu Ito.   

Abstract

UNLABELLED: We evaluated the feasibility of anti-1-amino-3-(18)F-fluorocyclobutyl-1-carboxylic acid (anti-(18)F-FACBC) in diagnosing prostate cancer (PCa), using a rat orthotopic prostate cancer transplantation (OPCT) model. Furthermore, using in vivo experiments, we examined the potential of anti-(18)F-FACBC for differentiating between PCa and inflammation and between PCa and benign prostatic hyperplasia (BPH).
METHODS: The OPCT model was developed by transplanting DU145, a human PCa cell line, into the ventral prostate of athymic F344 rats. To develop a dual PCa and inflammation (DPCI) model, MAT-Ly-Lu-B2--a rat PCa cell line--was transplanted subcutaneously into male Copenhagen rats. Streptozotocin was injected into the hind footpad of these rats for inducing popliteal lymphadenitis. For inducing the BPH, normal F344 rats were castrated and injected subcutaneously with testosterone propionate. In biodistribution studies, the rats were injected with anti-(18)F-FACBC or (18)F-FDG and sacrificed at 15 or 60 min after injection. We performed dynamic small-animal PET of the abdominal portion of the OPCT rats for 60 min after the injection of anti-(18)F-FACBC or (18)F-FDG.
RESULTS: The biodistribution in the OPCT rats at 60 min after injection showed that the uptake of anti-(18)F-FACBC and (18)F-FDG into the PCa tissue was 1.58 +/- 0.40 %ID/cm(3) (percentage injected dose per cm(3)) and 1.48 +/- 0.90 %ID/cm(3), respectively (P > 0.05). The accumulation of anti-(18)F-FACBC in the urinary bladder at 60 min after injection was 3.09 +/- 1.43 %ID/cm(3), whereas that of (18)F-FDG was 69.31 +/- 16.55 %ID/cm(3) (P < 0.05). Consequently, small-animal imaging with anti-(18)F-FACBC facilitated the visualization of the PCa tissue of the OPCT rats with higher contrast than (18)F-FDG. Furthermore, in comparison with (18)F-FDG, apparently higher ratios of PCa to inflammation and PCa to BPH accumulation of anti-(18)F-FACBC were demonstrated in the animal models.
CONCLUSION: FACBC PET is believed to be useful not only for the visualization of human PCa but also for differentiating between PCa and inflammation and between PCa and BHP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17204698

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  47 in total

1.  Preclinical characterization of 18F-D-FPHCys, a new amino acid-based PET tracer.

Authors:  Delphine Denoyer; Laura Kirby; Kelly Waldeck; Peter Roselt; Oliver C Neels; Thomas Bourdier; Rachael Shepherd; Andrew Katsifis; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12-13       Impact factor: 9.236

2.  Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer.

Authors:  Ying Chen; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Mrudula Pullambhatla; James J Fox; Mark Castanares; Shawn E Lupold; John W Babich; Ronnie C Mease; Martin G Pomper
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

Review 3.  A review of imaging agent development.

Authors:  Eric D Agdeppa; Mary E Spilker
Journal:  AAPS J       Date:  2009-05-05       Impact factor: 4.009

Review 4.  The evolution of imaging in cancer: current state and future challenges.

Authors:  Luke J Higgins; Martin G Pomper
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

Review 5.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

Review 6.  Novel Imaging in Detection of Metastatic Prostate Cancer.

Authors:  Clayton P Smith; Anna Laucis; Stephanie Harmon; Esther Mena; Liza Lindenberg; Peter L Choyke; Baris Turkbey
Journal:  Curr Oncol Rep       Date:  2019-03-05       Impact factor: 5.075

Review 7.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

8.  Initial experience with the radiotracer anti-1-amino-3-[18F]Fluorocyclobutane-1-carboxylic acid (anti-[ 18F]FACBC) with PET in renal carcinoma.

Authors:  David M Schuster; Jonathon A Nye; Peter T Nieh; John R Votaw; Raghuveer K Halkar; Muta M Issa; Weiping Yu; Julio Sepulveda; Wanzhen Zeng; Andrew Young; Mark M Goodman
Journal:  Mol Imaging Biol       Date:  2009-05-16       Impact factor: 3.488

9.  The clinical safety, biodistribution and internal radiation dosimetry of [¹⁸F]fluciclovine in healthy adult volunteers.

Authors:  Brian J McParland; Anders Wall; Silvia Johansson; Jens Sørensen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-24       Impact factor: 9.236

Review 10.  Positron emission tomography imaging of prostate cancer.

Authors:  Hao Hong; Yin Zhang; Jiangtao Sun; Weibo Cai
Journal:  Amino Acids       Date:  2009-11-28       Impact factor: 3.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.